Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...

For the first time, Eupraxia is reporting 24-week data on symptom response from the highest dose cohort in the open label, Phase 1b/2a portion of ...

Barclays 28th Annual Global Healthcare Conference March 10, 2026 8:30 AM EDTCompany ParticipantsDaniel Faga - President, CEO ...

Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-Q) from The Globe and Mail including charting and trades.

New research shows PPIs can limit fibrosis in eosinophilic oesophagitis, offering potential disease-modifying effects. Learn more about PPI therapy.

Raffle at Upcoming Islanders Game Will Support Eosinophilic Disease Research ATLANTA, GA, UNITED STATES, March 6, ...

CEO Daniel Faga outlined progress on the company’s planned separation into two entities, provided an update on its royalty ...

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March ...

Seasonal allergies are nothing to sniff at. Spring allergy season is worsening with each passing year, as winds carrying ...

Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize ...

Eupraxia Pharmaceuticals Inc. (EPRX) garnered retail attention on Tuesday after the biotech company reported positive data ...

Mr. James brings more than 20 years of biopharmaceutical leadership experience, with deep expertise in capital markets, investor relations, and corporate strategy, serving in senior executive roles at ...